Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRS005 in relapsed or refractory diffuse large B-cell lymphoma
NCT06886139Phase 2Not yet recruiting
- Sponsor
- Zhejiang Teruisi Pharmaceutical Inc.
- Start
- Sep 2025
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TRS005 in diffuse large B-cell lymphoma (DLBCL), sponsored by Zhejiang Teruisi Pharmaceutical Inc. Primary endpoint: Objective Response Rate up to 24 months. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
TRS005
03
Conditions
diffuse large B-cell lymphoma (DLBCL)
Beyond the preview
Go deeper on NCT06886139.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06886139.